Alterity Therapeutics (ATHE) Share-based Compensation (2017 - 2025)

Alterity Therapeutics has reported Share-based Compensation for 8 years, with the latest figure at -$2.9 million in Q4 2025.

• On a quarterly basis, Share-based Compensation fell 179.85% year-over-year to -$2.9 million in Q4 2025; TTM through Dec 2025 was -$5.2 million, a 46.07% decrease from a year earlier, with the FY2025 full-year figure at $627.6 billion, up 7.97% from the prior year.
• Share-based Compensation was -$2.9 million for Q4 2025 at Alterity Therapeutics, down from -$1.0 million in the prior quarter.
• The five-year high for Share-based Compensation was -$406591.7 in Q4 2023, with the low at -$2.9 million in Q4 2025.
• Average Share-based Compensation over 5 years is -$1.3 million, with a median of -$1.0 million recorded in 2024.
• The sharpest annual moves came in 2023 and 2025: Share-based Compensation jumped 50.67% in 2023, then plunged 179.85% in 2025.
• Over 5 years, Share-based Compensation stood at -$1.3 million in 2021, then soared by 35.37% to -$824198.4 in 2022, then soared by 50.67% to -$406591.7 in 2023, then tumbled by 155.64% to -$1.0 million in 2024, then slumped by 179.85% to -$2.9 million in 2025.
• The last three Share-based Compensation figures came in at -$2.9 million (Q4 2025), -$1.0 million (Q4 2024), and -$406591.7 (Q4 2023), per Business Quant data.